S J Luen1, R Salgado2, M V Dieci3, A Vingiani4, G Curigliano5, R E Gould6, C Castaneda7, T D'Alfonso8, J Sanchez7, E Cheng9, E Andreopoulou9, M Castillo7, S Adams10, S Demaria9, W F Symmans6, S Michiels11, S Loi12. 1. Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Australia. 2. Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Australia; Department of Pathology, GZA-ZNA Hospitals, Antwerp, Belgium. 3. University of Padova, Padova, Italy; Veneto Institute of Oncology IOV - IRCCS, Padua, Italy. 4. European Institute of Oncology IRCCS, Milan, Italy. 5. European Institute of Oncology IRCCS, Milan, Italy; University of Milano, Milan, Italy. 6. MD Anderson Cancer Centre, Houston, USA. 7. Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru. 8. Memorial Sloan Kettering Cancer Center, New York, USA. 9. Department of Radiation Oncology and Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, USA. 10. New York University School of Medicine, New York, USA. 11. Service de Biostatistique et d'Epidémiologie, Gustave Roussy, University Paris-Sud, University Paris-Saclay, Villejuif, France. 12. Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Australia. Electronic address: sherene.loi@petermac.org.
Abstract
BACKGROUND: For primary triple-negative breast cancer (TNBC) treated with neoadjuvant chemotherapy (NAC), higher pretreatment tumor-infiltrating lymphocytes (TILs) correlates with increased pathologic complete response (pCR) rates, and improved survival. We evaluated the added prognostic value of residual disease (RD) TILs to residual cancer burden (RCB) in predicting survival post-NAC. PATIENTS AND METHODS: We combined four TNBC NAC patient cohorts who did not achieve pCR. RD TILs were investigated for associations with recurrence-free survival (RFS), and overall survival (OS) using Cox models with stromal TILs as a continuous variable (per 10% increment). The likelihood ratio test was used to evaluate added prognostic value of RD TILs. RESULTS: A total of 375 RD TNBC samples were evaluable for TILs and RCB. The median age was 50 years, with 62% receiving anthracycline/taxane chemotherapy. The RCB class after NAC was 11%, 50%, and 39% for I, II, and III, respectively. The median RD TIL level was 20% (IQR 10-40). There was a positive correlation between RD TIL levels and CD8+ T-cell density (ρ = 0.41). TIL levels were significantly lower with increasing post-NAC tumor (P = 0.005), nodal stage (P = 0.032), but did not differ by RCB class (P = 0.84). Higher RD TILs were significantly associated with improved RFS (HR: 0.86; 95% CI 0.79-0.92; P < 0.001), and improved OS (HR: 0.87; 95% CI 0.80-0.94; P < 0.001), and remained significant predictors in multivariate analysis (RFS P = 0.032; OS P = 0.038 for OS). RD TILs added significant prognostic value to multivariate models including RCB class (P < 0.001 for RFS; P = 0.021 for OS). The positive prognostic effect of RD TILs significantly differed by RCB class for RFS (PInt=0.003) and OS (PInt=0.008) with a greater magnitude of positive effect observed for RCB class II than class III. CONCLUSIONS: TIL levels in TNBC RD are significantly associated with improved RFS and OS and add further prognostic information to RCB class, particularly in RCB class II.
BACKGROUND: For primary triple-negative breast cancer (TNBC) treated with neoadjuvant chemotherapy (NAC), higher pretreatment tumor-infiltrating lymphocytes (TILs) correlates with increased pathologic complete response (pCR) rates, and improved survival. We evaluated the added prognostic value of residual disease (RD) TILs to residual cancer burden (RCB) in predicting survival post-NAC. PATIENTS AND METHODS: We combined four TNBC NACpatient cohorts who did not achieve pCR. RD TILs were investigated for associations with recurrence-free survival (RFS), and overall survival (OS) using Cox models with stromal TILs as a continuous variable (per 10% increment). The likelihood ratio test was used to evaluate added prognostic value of RD TILs. RESULTS: A total of 375 RD TNBC samples were evaluable for TILs and RCB. The median age was 50 years, with 62% receiving anthracycline/taxane chemotherapy. The RCB class after NAC was 11%, 50%, and 39% for I, II, and III, respectively. The median RD TIL level was 20% (IQR 10-40). There was a positive correlation between RD TIL levels and CD8+ T-cell density (ρ = 0.41). TIL levels were significantly lower with increasing post-NACtumor (P = 0.005), nodal stage (P = 0.032), but did not differ by RCB class (P = 0.84). Higher RD TILs were significantly associated with improved RFS (HR: 0.86; 95% CI 0.79-0.92; P < 0.001), and improved OS (HR: 0.87; 95% CI 0.80-0.94; P < 0.001), and remained significant predictors in multivariate analysis (RFS P = 0.032; OS P = 0.038 for OS). RD TILs added significant prognostic value to multivariate models including RCB class (P < 0.001 for RFS; P = 0.021 for OS). The positive prognostic effect of RD TILs significantly differed by RCB class for RFS (PInt=0.003) and OS (PInt=0.008) with a greater magnitude of positive effect observed for RCB class II than class III. CONCLUSIONS: TIL levels in TNBC RD are significantly associated with improved RFS and OS and add further prognostic information to RCB class, particularly in RCB class II.
Authors: Zuzana Kos; Elvire Roblin; Rim S Kim; Stefan Michiels; Brandon D Gallas; Weijie Chen; Koen K van de Vijver; Shom Goel; Sylvia Adams; Sandra Demaria; Giuseppe Viale; Torsten O Nielsen; Sunil S Badve; W Fraser Symmans; Christos Sotiriou; David L Rimm; Stephen Hewitt; Carsten Denkert; Sibylle Loibl; Stephen J Luen; John M S Bartlett; Peter Savas; Giancarlo Pruneri; Deborah A Dillon; Maggie Chon U Cheang; Andrew Tutt; Jacqueline A Hall; Marleen Kok; Hugo M Horlings; Anant Madabhushi; Jeroen van der Laak; Francesco Ciompi; Anne-Vibeke Laenkholm; Enrique Bellolio; Tina Gruosso; Stephen B Fox; Juan Carlos Araya; Giuseppe Floris; Jan Hudeček; Leonie Voorwerk; Andrew H Beck; Jen Kerner; Denis Larsimont; Sabine Declercq; Gert Van den Eynden; Lajos Pusztai; Anna Ehinger; Wentao Yang; Khalid AbdulJabbar; Yinyin Yuan; Rajendra Singh; Crispin Hiley; Maise Al Bakir; Alexander J Lazar; Stephen Naber; Stephan Wienert; Miluska Castillo; Giuseppe Curigliano; Maria-Vittoria Dieci; Fabrice André; Charles Swanton; Jorge Reis-Filho; Joseph Sparano; Eva Balslev; I-Chun Chen; Elisabeth Ida Specht Stovgaard; Katherine Pogue-Geile; Kim R M Blenman; Frédérique Penault-Llorca; Stuart Schnitt; Sunil R Lakhani; Anne Vincent-Salomon; Federico Rojo; Jeremy P Braybrooke; Matthew G Hanna; M Teresa Soler-Monsó; Daniel Bethmann; Carlos A Castaneda; Karen Willard-Gallo; Ashish Sharma; Huang-Chun Lien; Susan Fineberg; Jeppe Thagaard; Laura Comerma; Paula Gonzalez-Ericsson; Edi Brogi; Sherene Loi; Joel Saltz; Frederick Klaushen; Lee Cooper; Mohamed Amgad; David A Moore; Roberto Salgado Journal: NPJ Breast Cancer Date: 2020-05-12
Authors: F Giugliano; J Uliano; V A A Zia; D Trapani; A Marra; G Viale; E Ferraro; A Esposito; C Criscitiello; P D'amico; G Curigliano Journal: Breast Cancer Res Treat Date: 2021-05-27 Impact factor: 4.872
Authors: Margaret L Axelrod; Mellissa J Nixon; Paula I Gonzalez-Ericsson; Riley E Bergman; Mark A Pilkinton; Wyatt J McDonnell; Violeta Sanchez; Susan R Opalenik; Sherene Loi; Jing Zhou; Sean Mackay; Brent N Rexer; Vandana G Abramson; Valerie M Jansen; Simon Mallal; Joshua Donaldson; Sara M Tolaney; Ian E Krop; Ana C Garrido-Castro; Jonathan D Marotti; Kevin Shee; Todd W Miller; Melinda E Sanders; Ingrid A Mayer; Roberto Salgado; Justin M Balko Journal: Clin Cancer Res Date: 2020-08-21 Impact factor: 12.531
Authors: Balazs Acs; David L Rimm; Yalai Bai; Kimberly Cole; Sandra Martinez-Morilla; Fahad Shabbir Ahmed; Jon Zugazagoitia; Johan Staaf; Ana Bosch; Anna Ehinger; Emma Nimeus; Johan Hartman Journal: Clin Cancer Res Date: 2021-06-04 Impact factor: 12.531
Authors: Victor Sarradin; Amélie Lusque; Thomas Filleron; Florence Dalenc; Camille Franchet Journal: Breast Cancer Res Date: 2021-05-26 Impact factor: 6.466
Authors: Mercedes Herrera Juarez; Pablo Tolosa Ortega; Ana Sanchez de Torre; Eva Ciruelos Gil Journal: Breast Care (Basel) Date: 2020-06-05 Impact factor: 2.860